Insulet (NASDAQ:PODD) Shares Up 4.9% – What’s Next?

Shares of Insulet Corporation (NASDAQ:PODD) rose 4.9% during trading on Tuesday . The stock traded as high as $145.87 and last traded at $146.5610. 92,700 shares were traded during trading, a decline of 93% from the average session volume of 1,310,668 shares. The stock had previously closed at $139.70.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet insiders have been net buyers over the past six months, including CEO Ashley McEvoy’s reported purchase of approximately 4,300 shares. Analysts also remain broadly constructive, with recent “Outperform” and “Overweight” ratings and a median price target substantially above the current trading level. Why Insulet Stock Is Down Today
• Neutral Sentiment: Multiple law firms are reminding shareholders that August 31, 2026 is the deadline to seek appointment as lead plaintiff in a federal class action involving investors who purchased Insulet securities during a period generally spanning February 21, 2025, through May 26, 2026. These notices are largely duplicative and do not represent a new judgment against the company. Insulet Shareholder Notice
• Negative Sentiment: The lawsuits allege that Insulet and certain executives violated federal securities laws by making misleading statements or omissions related to defective Omnipod manufacturing controls. The allegations have not been proven, but continued litigation could increase legal costs and investor uncertainty, particularly because the CEO and CFO are named as individual defendants in some filings. Insulet Securities Class Action Alert
• Negative Sentiment: Investors are also focused on weaker forward Omnipod growth expectations following the latest earnings update. Although Insulet exceeded quarterly earnings and revenue estimates, softer guidance and a prior medical-device correction affecting certain Pods have raised concerns about U.S. demand, manufacturing execution and recall-related risks. Why Insulet Stock Is Down Today

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 9th. Stifel Nicolaus dropped their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Raymond James Financial restated an “outperform” rating and set a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. Finally, UBS Group lowered their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $195.40.

Insulet Price Performance

The stock’s 50-day moving average is $154.96 and its 200-day moving average is $187.34. The firm has a market cap of $10.14 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Insulet during the second quarter valued at approximately $1,018,582,000. Norges Bank acquired a new stake in Insulet during the fourth quarter worth $300,794,000. Arrowstreet Capital Limited Partnership boosted its stake in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Man Group plc bought a new stake in Insulet in the 2nd quarter valued at $78,746,000. Finally, Bank of America Corp DE bought a new stake in Insulet in the 2nd quarter valued at $64,921,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.